

REMARKS

Claims 1-22 are presented in this application. In this amendment, claims 3-8, 12-15, 18 and 21 have been amended to place them in form appropriate to US practice and to remove multiple dependencies for the purpose of reducing fees.

Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted on accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,




James P. Riek
Attorney for Applicant
Registration No. 39,009

Date: January 11, 2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8022
Facsimile: 919-483-7988

ABSTRACT

A compound of formula (I):



wherein

X represents O or S;

R₁ represents C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkylmethyl or C₃₋₈ cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R₁ represents aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R₂ represents hydrogen, methyl, which may be in either the α or β configuration, or methylene;

R₃ and R₄ are the same or different and each independently represents hydrogen, halogen or a methyl group;

and --- represents a single or a double bond;

or a physiologically acceptable salt or solvate thereof.